![Medicine doctor touching and diagnose electronic medical record of patient on interface](https://www.brookings.edu/wp-content/uploads/2024/07/shutterstock_1931406860.jpg?quality=75&w=500)
![Medicine doctor touching and diagnose electronic medical record of patient on interface](https://www.brookings.edu/wp-content/uploads/2024/07/shutterstock_1931406860.jpg?quality=75&w=500)
9:00 am EST - 11:15 am EST
Past Event
9:00 am - 11:15 am EST
1775 Massachusetts Avenue N.W.
Washington, DC
20036
Prescription drug costs continue to grow in the U.S. due to both price hikes for existing drugs and the development of expensive new therapies. In Medicare, these costs now account for $1 out of every $6 in spending . As costs grow, particularly for specialty drugs and novel therapies, patients can face high cost-sharing burdens, and the Medicare benefit places no limit on a patient’s out-of-pocket spending for prescription drugs. Moreover, while increased rebates have often mitigated the growth in net drug prices, many patients still pay cost-sharing based on a percentage of the gross (pre-rebate) drug price.
On Friday, February 16, the USC-Brookings Schaeffer Initiative for Health Policy hosted a conference on the policy issues surrounding patient drug cost sharing. Two panels convened, first to discuss restructuring the Medicare Part D benefit design, and then to debate the effectiveness of mechanisms to reduce cost sharing for commercially insured patients.
9:00 am - 9:05 am
9:05 am - 10:00 am
Panelist
10:00 am - 11:15 am
Panelist
Gavin Yamey, Shingai Machingaidze, Osondu Ogbuoji, Marco Schäferhoff
July 22, 2024
Wendell Primus, Vani Agarwal, Caitlin Rowley
July 22, 2024
Vani Agarwal, Chloe Zilkha, Richard G. Frank
July 16, 2024